Phaseline

Companies › Nanjing Legend Biotech

Nanjing Legend Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LUCAR-G79D T cells
CAR-T cells targeting CD79, engineered for treatment of B-cell mediated autoimmune disease
–Phase 1Systemic Lupus Erythematosus (SLE)Jan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07331272LUCAR-G79D T cellsPhase 1Systemic Lupus Erythematosus (SLE)ImmunologyJan 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.